BCR and Familial prostate cancer: Both intermediate- and high-risk prostate cancer patients with an interval from biopsy to RP >3 and ≤6 months did not differ from those treated within 3 months after biopsy, regarding adverse pathologic outcomes and BCR rates after RP.